Venture Fund Xi L.P. Atlas Sells 154,674 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYNGet Free Report) major shareholder Venture Fund Xi L.P. Atlas sold 154,674 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $24.84, for a total transaction of $3,842,102.16. Following the completion of the transaction, the insider now directly owns 5,698,091 shares of the company’s stock, valued at approximately $141,540,580.44. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Venture Fund Xi L.P. Atlas also recently made the following trade(s):

  • On Monday, February 26th, Venture Fund Xi L.P. Atlas sold 201,095 shares of Dyne Therapeutics stock. The shares were sold at an average price of $23.72, for a total transaction of $4,769,973.40.
  • On Friday, February 23rd, Venture Fund Xi L.P. Atlas sold 159,542 shares of Dyne Therapeutics stock. The shares were sold at an average price of $22.70, for a total transaction of $3,621,603.40.
  • On Wednesday, February 21st, Venture Fund Xi L.P. Atlas sold 184,501 shares of Dyne Therapeutics stock. The shares were sold at an average price of $22.57, for a total transaction of $4,164,187.57.
  • On Friday, February 16th, Venture Fund Xi L.P. Atlas sold 162,707 shares of Dyne Therapeutics stock. The shares were sold at an average price of $23.14, for a total transaction of $3,765,039.98.

Dyne Therapeutics Trading Up 1.5 %

Shares of NASDAQ:DYN traded up $0.38 during midday trading on Wednesday, hitting $24.98. The stock had a trading volume of 1,756,961 shares, compared to its average volume of 2,515,651. The company has a market capitalization of $1.53 billion, a PE ratio of -6.96 and a beta of 0.87. The stock has a 50 day moving average price of $19.02 and a two-hundred day moving average price of $13.05. Dyne Therapeutics, Inc. has a 1 year low of $6.40 and a 1 year high of $25.50.

Wall Street Analyst Weigh In

A number of research analysts have commented on DYN shares. StockNews.com upgraded shares of Dyne Therapeutics to a “sell” rating in a research note on Thursday, December 21st. HC Wainwright started coverage on shares of Dyne Therapeutics in a research note on Tuesday, February 20th. They issued a “buy” rating and a $36.00 price objective on the stock. Finally, Raymond James lifted their price objective on shares of Dyne Therapeutics from $27.00 to $56.00 and gave the company a “strong-buy” rating in a research note on Thursday, January 4th. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.50.

Read Our Latest Research Report on DYN

Institutional Trading of Dyne Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. boosted its holdings in Dyne Therapeutics by 26.8% during the second quarter. BlackRock Inc. now owns 3,322,187 shares of the company’s stock worth $37,375,000 after buying an additional 702,966 shares in the last quarter. Wasatch Advisors LP boosted its holdings in Dyne Therapeutics by 16.2% during the first quarter. Wasatch Advisors LP now owns 2,927,278 shares of the company’s stock worth $33,722,000 after buying an additional 407,699 shares in the last quarter. VR Adviser LLC purchased a new stake in Dyne Therapeutics during the second quarter worth about $24,457,000. Goldman Sachs Group Inc. boosted its holdings in Dyne Therapeutics by 34.5% during the second quarter. Goldman Sachs Group Inc. now owns 2,009,529 shares of the company’s stock worth $22,607,000 after buying an additional 515,079 shares in the last quarter. Finally, Franklin Resources Inc. boosted its holdings in Dyne Therapeutics by 1.1% during the second quarter. Franklin Resources Inc. now owns 1,913,479 shares of the company’s stock worth $21,527,000 after buying an additional 21,120 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

(Get Free Report)

Dyne Therapeutics, Inc, a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Featured Articles

Insider Buying and Selling by Quarter for Dyne Therapeutics (NASDAQ:DYN)

Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.